Literature DB >> 19643241

Cost-effectiveness of vasectomy reversal.

Paul Robb1, Jay I Sandlow.   

Abstract

In this era of cost-consciousness and containment, it is imperative to examine not only treatment outcomes but also cost of these treatments. With improvements of in vitro fertilization outcome and continued development of less-invasive sperm retrieval methods, physicians and couples must examine all options available after surgical sterilization. Vasectomy reversal remains the gold standard of treatment; however, certain situations may be present in which sperm acquisition/in vitro fertilization may be a better option. A physician's responsibility is to present all options with the pros and cons of each, including cost, to help arrive at an informed decision.

Entities:  

Mesh:

Year:  2009        PMID: 19643241     DOI: 10.1016/j.ucl.2009.05.003

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  5 in total

Review 1.  Surgical treatment of male infertility in the era of intracytoplasmic sperm injection - new insights.

Authors:  Sandro C Esteves; Ricardo Miyaoka; Ashok Agarwal
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 2.  Current status of vasectomy reversal.

Authors:  J Ullrich Schwarzer; Heiko Steinfatt
Journal:  Nat Rev Urol       Date:  2013-02-12       Impact factor: 14.432

3.  A retrospective review of factors associated with vasovasostomies in United States military members.

Authors:  J Masterson; E Avalos; M Santomauro; R Walters; C Marguet; J L'Esperance; D Crain
Journal:  Curr Urol       Date:  2012-12-21

4.  Vasectomy Reversal must be the first step for a man who had a vasectomy and wants a children from a new marriage? Opinion: Yes.

Authors:  Marcelo Vieira
Journal:  Int Braz J Urol       Date:  2015 Nov-Dec       Impact factor: 1.541

5.  Vasectomy Reversal must be the first step for a man who had a vasectomy and wants a children from a new marriage? Opinion: No.

Authors:  Kelly A Chiles; Peter N Schlegel
Journal:  Int Braz J Urol       Date:  2015 Nov-Dec       Impact factor: 1.541

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.